AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18312050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 16998403 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet fortified with fish oil and arginine (FAD)
Number of subjects: 23
Study 16998403 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (STD)
Number of subjects: 23
Study 14550817 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) for 6 months
Number of subjects: 25
Study 14550817 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) and resistance exercises for 6 months
Number of subjects: 25
Study 14550817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 10933364 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 50 mg three times a day
Number of subjects: 105
Study 10933364 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 25 mg three times a day
Number of subjects: 105
Study 10933364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 8881096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild aversion (painting a bitter substance on nails)
Number of subjects: 45
Study 8881096 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing response (performing a competing response when the urge to nailbite occurred)
Number of subjects: 45
Study 8881096 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring alone
Number of subjects: 45
Study 1546770 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-session enhanced intervention
Number of subjects: 567
Study 1546770 — intervention group
Group type: COMPARATOR
Intervention: Two-session informational intervention (early)
Number of subjects: 567
Study 1546770 — intervention group
Group type: COMPARATOR
Intervention: Two-session informational intervention (late)
Number of subjects: 567
Study 1546770 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including enhanced and informational)
Number of subjects: 567
Study 3945199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (written information about medications and behavioral strategies)
Number of subjects: 196
Study 3945199 — intervention group
Group type: COMPARATOR
Intervention: Control (received no intervention)
Number of subjects: 196
Study 30181143 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA (fish oil)
Number of subjects: 736
Study 30181143 — intervention group
Group type: COMPARATOR
Intervention: Control (olive oil)
Number of subjects: 736
Study 25831408 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching + TENS
Number of subjects: 51
Study 25831408 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Stretching (AS)
Number of subjects: 51
Study 25831408 — intervention group
Group type: COMPARATOR
Intervention: Conventional Stretching
Number of subjects: 51
Study 25335329 — intervention group
Group type: EXPERIMENTAL
Intervention: Shugan Jiangu Recipe (SJR), 6 g twice daily for 6 months
Number of subjects: 38
Study 25335329 — intervention group
Group type: COMPARATOR
Intervention: Caltrate D Tablet (Ca 600 mg and Vit D3 125 IU), one tablet daily
Number of subjects: 38
Study 25335329 — intervention group
Group type: EXPERIMENTAL
Intervention: Shugan Jiangu Recipe (SJR)
Number of subjects: 38
Study 22861490 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents
Number of subjects: 53
Study 22861490 — intervention group
Group type: COMPARATOR
Intervention: Native stents
Number of subjects: 53
Study 15838525 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of DHA and 0.75 g of EPA daily for 6 months
Number of subjects: 19
Study 11996329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet formulation of R115777 (300 or 400 mg)
Number of subjects: 24
Study 11996329 — intervention group
Group type: COMPARATOR
Intervention: Capsule formulation of R115777 (300 or 400 mg)
Number of subjects: 24
Study 9702468 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (BAY m 1099), 100 mg tds
Number of subjects: 117
Study 9702468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 7865987 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone injection
Number of subjects: 20
Study 7865987 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking two cigarettes of the subject's preferred brand
Number of subjects: 20
Study 7865987 — intervention group
Group type: COMPARATOR
Intervention: Ergometry
Number of subjects: 20
Study 7865987 — intervention group
Group type: COMPARATOR
Intervention: Psychological stress
Number of subjects: 20
Study 7865987 — intervention group
Group type: COMPARATOR
Intervention: Circadian rhythm measurement of salivary cortisol
Number of subjects: 20
Study 2685532 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g aspirin + 0.3 g calcium carbonate (chewed before swallowing)
Number of subjects: 18
Study 2685532 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g plain aspirin (swallowed)
Number of subjects: 18
Study 800971 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% desoxymethasone ointment
Number of subjects: 56
Study 800971 — intervention group
Group type: COMPARATOR
Intervention: 0.05% fluocinonide ointment
Number of subjects: 56
Study 30173089 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (≥2 days a week for ≥20 min each day)
Number of subjects: 300
Study 30173089 — intervention group
Group type: COMPARATOR
Intervention: No exercise group (<2 days a week for ≥20 min each day)
Number of subjects: 300
Study 27297851 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.05-0.2 μg/[kg min])
Number of subjects: 1000
Study 27297851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 24053564 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg twice daily)
Number of subjects: 89
Study 24053564 — intervention group
Group type: COMPARATOR
Intervention: placebo (two tablets twice daily)
Number of subjects: 89
Study 22323708 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased oscillatory alpha/beta power over the hemisphere housing the competitor memory trace
Number of subjects: 18
Study 22323708 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition where competitor memory interfered with target retrieval
Number of subjects: 18
Study 20192140 — intervention group
Group type: COMPARATOR
Intervention: Screw proximal femoral nails
Number of subjects: 40
Study 20192140 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical proximal femoral nails
Number of subjects: 40
Study 18528794 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered arm (patient's own clothing of maximally 2 mm thickness)
Number of subjects: 203
Study 18528794 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare arm
Number of subjects: 203
Study 18528794 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm covered with a standardized cotton sleeve (2 mm)
Number of subjects: 203
Study 16136931 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-letting puncture at Twelve Well-Points of Hand
Number of subjects: 0
Study 16136931 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 0
Study 12412834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (300 mg/day)
Number of subjects: 9
Study 12412834 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (450 mg/day)
Number of subjects: 9
Study 12412834 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral delta9-THC (10, 20, 30 mg PO)
Number of subjects: 9
Study 12412834 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked marijuana (0.0%, 1.8%, 2.8%, 3.9% THC)
Number of subjects: 9
Study 12412834 — intervention group
Group type: COMPARATOR
Intervention: Placebo marijuana (0.0% THC)
Number of subjects: 9
Study 10048645 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque index scoring method
Number of subjects: 15
Study 10048645 — intervention group
Group type: COMPARATOR
Intervention: Plaque area scoring method
Number of subjects: 15
Study 7887710 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 415
Study 7887710 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 415
Study 2403818 — intervention group
Group type: COMPARATOR
Intervention: 7‐3 regimen (cytosine arabinoside 100 mg/m2/d IV days 1-7, daunorubicin 50 mg/m2/d IV days 1-3)
Number of subjects: 264
Study 2403818 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐3‐7 regimen (same drugs intensified with etoposide 75 mg/m2/d IV days 1-7)
Number of subjects: 264
Study 2403818 — intervention group
Group type: COMPARATOR
Intervention: Subset analysis for patients < 55 years with 7‐3 regimen
Number of subjects: 264
Study 2403818 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset analysis for patients < 55 years with 7‐3‐7 regimen
Number of subjects: 264
Study 2403818 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset analysis for patients ≥ 55 years with 7‐3‐7 regimen
Number of subjects: 264
Study 2403818 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction courses for both regimens
Number of subjects: 264
Study 2403818 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation courses for both regimens
Number of subjects: 264
Study 362121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine prophylaxis
Number of subjects: 13
Study 362121 — intervention group
Group type: COMPARATOR
Intervention: Control (no lidocaine)
Number of subjects: 13
Study 30904553 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous implant and CTG placement (test group)
Number of subjects: 14
Study 30904553 — intervention group
Group type: COMPARATOR
Intervention: Implant placement followed by CTG placement after 3 months (control group)
Number of subjects: 14
Study 28404450 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery position
Number of subjects: 59
Study 28404450 — intervention group
Group type: COMPARATOR
Intervention: Head tilt and chin lift
Number of subjects: 59
Study 26080189 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed SRP
Number of subjects: 50
Study 26080189 — intervention group
Group type: COMPARATOR
Intervention: Open SRP
Number of subjects: 50
Study 23938312 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided reading group (CBT based self-help resource: What? Me Worry!?!, 8 weeks duration, with telephone support at 2 week intervals)
Number of subjects: 54
Study 23938312 — intervention group
Group type: COMPARATOR
Intervention: Control group (information about worry only, one phone call)
Number of subjects: 54
Study 21207089 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulation
Number of subjects: 10
Study 21207089 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCAM-funded chiropractic studies
Number of subjects: 10
Study 19624476 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted vector control intervention (focusing on the most productive water container types)
Number of subjects: 8
Study 19624476 — intervention group
Group type: COMPARATOR
Intervention: Non-targeted vector control intervention (attempting to reach all water holding containers)
Number of subjects: 8
Study 19624476 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted vector control intervention
Number of subjects: 8
Study 19624476 — intervention group
Group type: COMPARATOR
Intervention: Non-targeted vector control intervention
Number of subjects: 8
Study 16424413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast, 15 mg bid
Number of subjects: 0
Study 16424413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15142864 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 42
Study 15142864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 15142864 — intervention group
Group type: COMPARATOR
Intervention: Healthy nondiabetic subjects
Number of subjects: 42
Study 11355925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy including high-dose Ara-C
Number of subjects: 0
Study 11355925 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Number of subjects: 0
Study 11355925 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvements in supportive care
Number of subjects: 0
Study 11355925 — intervention group
Group type: EXPERIMENTAL
Intervention: Future advances in paediatric AML treatment
Number of subjects: 0
Study 9397386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 micrograms/day and NETA (170 micrograms/day) given continuously
Number of subjects: 774
Study 9397386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 micrograms/day and NETA (350 micrograms/day) given continuously
Number of subjects: 774
Study 9397386 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 micrograms/day and NETA given sequentially (last 14 days of each treatment cycle)
Number of subjects: 774
Study 9397386 — intervention group
Group type: COMPARATOR
Intervention: Oral progestogen (1 mg/day NET or 20 mg/day dydrogesterone) with transdermal estradiol 50 micrograms/day
Number of subjects: 774
Study 7949797 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF alpha plasma concentration (> 70 pg/ml)
Number of subjects: 55
Study 7949797 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐6 plasma concentration (> 500 pg/ml)
Number of subjects: 55
Study 7949797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TNF alpha and IL‐6 tests
Number of subjects: 55
Study 3148036 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (12 mg/kg.day)
Number of subjects: 16
Study 3148036 — intervention group
Group type: COMPARATOR
Intervention: Carnitine-free total parenteral nutrition (TPN)
Number of subjects: 16
Study 31306748 — intervention group
Group type: COMPARATOR
Intervention: TB-related gene-set
Number of subjects: 5512
Study 31306748 — intervention group
Group type: COMPARATOR
Intervention: TB (Mendelian Randomization)
Number of subjects: 5512
Study 29263124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie formula (27 infants, 24 kcal/oz)
Number of subjects: 49
Study 29263124 — intervention group
Group type: COMPARATOR
Intervention: Standard-calorie formula (22 infants, 20 kcal/oz)
Number of subjects: 49
Study 27626242 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gastric bypass (alimentary limb, 150 cm)
Number of subjects: 113
Study 27626242 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal gastric bypass (common channel, 150 cm)
Number of subjects: 113
Study 27626242 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal gastric bypass
Number of subjects: 113
Study 27626242 — intervention group
Group type: COMPARATOR
Intervention: Standard gastric bypass
Number of subjects: 113
Study 24670418 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD)
Number of subjects: 40
Study 24670418 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AF
Number of subjects: 40
Study 23452524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice application (flexible and bendable cold gel packs wrapped in fine cloth sheaths) applied to the chest tube insertion site at the 24th, 28th, 36th, and 40th postoperative hours for 20 minutes.
Number of subjects: 40
Study 23452524 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative analgesic methods (applied to all patients).
Number of subjects: 40
Study 20472114 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 mcg)
Number of subjects: 89
Study 20472114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 18786299 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg BID for 1 week, then 10 microg BID for 1 week)
Number of subjects: 61
Study 18786299 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg QAM for 2 weeks)
Number of subjects: 61
Study 18786299 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 61
Study 15967730 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress echocardiography (SE)
Number of subjects: 302
Study 15967730 — intervention group
Group type: COMPARATOR
Intervention: Exercise electrocardiography (ExECG)
Number of subjects: 302
Study 12828433 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser exposure for 5 seconds
Number of subjects: 86
Study 12828433 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser exposure for 10 seconds
Number of subjects: 86
Study 12828433 — intervention group
Group type: COMPARATOR
Intervention: Visible light control
Number of subjects: 86
Study 10382130 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubes task (no arbitrary and novel rules)
Number of subjects: 0
Study 10382130 — intervention group
Group type: EXPERIMENTAL
Intervention: Day/night task (verbal output)
Number of subjects: 0
Study 10382130 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 8908384 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor ramipril
Number of subjects: 3657
Study 8908384 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 3657
Study 8908384 — intervention group
Group type: COMPARATOR
Intervention: Placebo for ACE inhibitor
Number of subjects: 3657
Study 8908384 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Vitamin E
Number of subjects: 3657
Study 8908384 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor ramipril and Vitamin E
Number of subjects: 3657
Study 8908384 — intervention group
Group type: COMPARATOR
Intervention: Placebo for ACE inhibitor and Vitamin E
Number of subjects: 3657
Study 1874200 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75% isoflurane
Number of subjects: 36
Study 1874200 — intervention group
Group type: COMPARATOR
Intervention: 2.5% halothane
Number of subjects: 36
Study 6580060 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinduction MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) for an additional 6 months
Number of subjects: 209
Study 6580060 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction BVCPP (BCNU, vinblastine, cyclophosphamide, procarbazine, and prednisone) for 6 months
Number of subjects: 209
Study 6580060 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 209
Study 29579136 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis Threat (DT) condition
Number of subjects: 0
Study 29579136 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-neutral condition
Number of subjects: 0
Study 29579136 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype lift condition
Number of subjects: 0
Study 29204914 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LLLT (820 nm wavelength, 30 mW, energy total 18 J)
Number of subjects: 20
Study 29204914 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT (pLLLT)
Number of subjects: 20
Study 27338216 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Medicine
Number of subjects: 119
Study 27338216 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Medicine
Number of subjects: 119
Study 27338216 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Radiology
Number of subjects: 119
Study 24928832 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (50 mg/day)
Number of subjects: 124
Study 24928832 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (250 mg/m2/week)
Number of subjects: 124
Study 24928832 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (stage II)
Number of subjects: 124
Study 24928832 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (stage II)
Number of subjects: 124
Study 22076647 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafton DBM Matrix with local bone
Number of subjects: 46
Study 22076647 — intervention group
Group type: COMPARATOR
Intervention: Autologous ICBG
Number of subjects: 46
Study 19063830 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty
Number of subjects: 0
Study 17459185 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (n = 60)
Number of subjects: 60
Study 17459185 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n = 60)
Number of subjects: 60
Study 17459185 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed comparison group (n = 56)
Number of subjects: 60
Study 14979400 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 20
Study 14979400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11341486 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 25
Study 11341486 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 25
Study 11341486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9738217 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anastomoses
Number of subjects: 200
Study 9738217 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn anastomoses
Number of subjects: 200
Study 7996346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered immune globulin, 0.5 gm/kg per day for 5 consecutive days (n = 19)
Number of subjects: 57
Study 7996346 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered methylprednisolone, 30 mg/kg per day for 7 days (n = 19)
Number of subjects: 57
Study 7996346 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered methylprednisolone, 50 mg/kg per day for 7 days (n = 19)
Number of subjects: 57
Study 3281399 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg, suppositories, 3 times a day for 3 days)
Number of subjects: 46
Study 3281399 — intervention group
Group type: COMPARATOR
Intervention: Placebo (suppositories, 3 times a day for 3 days)
Number of subjects: 46
Study 1555873 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circuit (Carmeda)
Number of subjects: 18
Study 1555873 — intervention group
Group type: COMPARATOR
Intervention: Non-heparin-coated extracorporeal circuit (Scimed)
Number of subjects: 18
Study 638969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional BCG therapy
Number of subjects: 8
Study 638969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol, rifampin, and prednisolone therapy
Number of subjects: 8
Study 638969 — intervention group
Group type: COMPARATOR
Intervention: Control group (melanoma not receiving BCG)
Number of subjects: 8
Study 30826774 — intervention group
Group type: EXPERIMENTAL
Intervention: ianalumab 3 mg/kg
Number of subjects: 27